The pursuit of outperformance leads many investors to carefully choose individual stocks. Picking the right ones can be a game-changer for growing your wealth.
As of close of business last night, ImmunityBio Inc’s stock clocked out at $3.00, up 0.33% from its previous closing price of $2.99. In other words, the price has increased by $0.33 from its previous closing price. On the day, 4.11 million shares were traded.
Ratios:
To gain a deeper understanding of IBRX’s stock, we examine its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 3.21 and its Current Ratio is at 3.36.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, H.C. Wainwright on March 06, 2025, initiated with a Buy rating and assigned the stock a target price of $8.
On January 10, 2025, BTIG Research started tracking the stock assigning a Buy rating and target price of $6.
Piper Sandler Downgraded its Overweight to Neutral on May 12, 2023, whereas the target price for the stock was revised from $10 to $4.
Valuation Measures:
For the stock, the TTM Price-to-Sale (P/S) ratio is 173.70.
Stock Price History:
Over the past 52 weeks, IBRX has reached a high of $10.53, while it has fallen to a 52-week low of $2.28. The 50-Day Moving Average of the stock is -1.10%, while the 200-Day Moving Average is calculated to be -31.75%.
Shares Statistics:
A total of 852.74M shares are outstanding, with a floating share count of 88.78M. Insiders hold about 89.60% of the company’s shares, while institutions hold 9.91% stake in the company.
